What The Study Did: This randomized clinical trials reports that among adults with mild COVID-19, a five-day course of ivermectin, compared with placebo, didn't significantly improve the time to resolution of symptoms. The findings don't support the use of ivermectin for treatment of mild COVID-19, although larger trials may be needed to understand the effects of ivermectin on other clinically relevant outcomes.
Authors: Eduardo López-Medina, M.D., M.Sc., of the Centro de Estudios en Infectología Pediátrica in Cali, Colombia, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jama.2021.3071)
Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
###
Media advisory: The full study is linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2021.3071?guestAccessKey=e98010ef-e747-40ad-b865-a18c9c0450d9&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=030421
JAMA